Recently, China Biopharmaceutical Co., Ltd. announced its interim results announcement. In the first half of 2018, the company's revenue reached 972.23 million yuan, an increase of about 30% over the same period of last year. The profit attributable to owners of the parent company reached 136.567 million yuan, an increase over the same period last year. About 24.1%. New product sales accounted for approximately 14.5% of the Group's revenue.
China Biopharmaceuticals is strong, and in 2016 and 2017, it is ranked among the top 50 Asia Pacific Best Companies in Forbes Asia. Its subsidiaries are also among the best in the domestic pharmaceutical industry, such as Zhengda Tianqing Pharmaceutical Co., Ltd., Beijing Tide Pharmaceutical Co., Ltd., Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., and Lianyungang Runzhong Pharmaceutical Co., Ltd. Company, etc. The research and development center of Zhengda Tianqing is a postdoctoral research station, and it is the only new research center for liver disease medicine engineering technology in China. Beijing Ted was recognized by the Japanese Ministry of Health, Labor and Welfare in 2012.
Many fields have become the industry's best producers
China's biopharmaceutical products are rich in a variety of biopharmaceuticals and chemical drugs, and are in a strong position in many potentially promising therapeutic areas such as cancer, liver disease, cardiovascular and cerebrovascular diseases, analgesia, respiratory medicine, and orthopedic diseases. In the first half of 2018, the performance of major areas is shown in the table below. It can be seen that cardiovascular and cerebrovascular, anti-tumor drugs and analgesics contribute significantly to the company's income.
In these major areas of contribution, their competitive products are domestic star drugs, the specific list is as follows:
According to the company's development, the drugs with the most potential for development are as follows:
1.3 billion R&D investment, 10 production approvals in half a year
New drug, consistency evaluation, full of competitiveness
China Biopharmaceuticals has always focused on drug research and development. In the first half of 2018, R&D investment reached 138.18 million yuan, accounting for 13.7% of revenue. High investment and strong strength made its research and development achievements very high. In the first half of the year, China Biopharmaceuticals obtained a total of 10 production approvals and 14 clinical approvals, including 13 drugs in class 1.1 and 1 in biological products. 3 cases were clinically evaluated; 2 were evaluated by consistency, and 8 were newly evaluated for consistency; currently there are 482 pieces of research products with clinical approvals, ongoing clinical trials, and declared production. During the reporting period, the Group also obtained 60 patents, including 45 invention patents; 145 new patent applications, including 141 invention patents. The important performance of the results is as follows:
1. The heavy innovative drug listed on the market for erlotinib HCl
In May 2018, Zhengda Tianqing's small-molecule multi-target receptor tyrosine kinase inhibitor, erlotinib hydrochloride (Focco) was marketed for the treatment of advanced or metastatic non-small cell lung cancer. The penolidine hydrochloride capsule belongs to the innovative drug independently developed by Zhengda Tianqing and is approved for listing through the priority review and approval process.
2. China's first neuropathic pain topical patch lidocaine gel paste was approved for marketing
In the first half of the year, the drug-lidocaine gel plaster developed by the subsidiary Beijing Tide Pharmaceutical Co., Ltd. was approved. The product is a new class of 3.1 drugs and has been monitored for four years. The drug is listed as a first-class recommended drug in clinical guidelines in many parts of the United States, Europe, and China. The drug was approved, which also marks the official launch of the first topical therapeutic patch in the field of neuropathic pain in China, filling the domestic gap.
3. The first imitation acetic acid ganirelix injection was approved
In May, the drug developed by Zhengda Tianqing was added to the drug in the first imitation market. The product was developed and produced by Merck. The product was named Orgalutran and entered China in June 2013. . According to public information, since the listing, the sales trend of Garnirik has been good. With the liberalization of China’s second-child policy and the growing age of the population, the domestic market of Garnirik will be more promising.
4. Runzhong (Entecavir dispersible tablets) passed the consistency evaluation
In March 2018, Runzhong (Entecavir dispersible film) passed the consistency evaluation, Runzhong as one of Zhengda Tianqing's fist products, quickly occupied the market with its curative effect and appropriate price, and emerged as the main anti-hepatitis B virus drug in China. product. In 2017, its market share was 44%. At present, the disperse film of Jiangxi Qingfeng has also passed the consistency evaluation, and the two have leading advantages.
5. Eurel (irbesartan hydrochlorothiazide tablets) passed the consistency evaluation
In March, the antihypertensive drug Yilunping (irbesartan hydrochlorothiazide tablets) was evaluated by consistency. Irbesartan hydrochlorothiazide tablets were suitable for patients with essential hypertension who could not effectively control blood pressure with irbesartan or hydrochlorothiazide alone. According to the 2017 annual report, the sales of Yilun Ping Film in 2017 was 634 million yuan, a year-on-year increase of 17.9%. To a certain extent, the market performance has already surpassed the original research. There are 9 companies in the domestic market that have the drug approval, and 4 tablet manufacturers. There are currently three companies that have submitted a conformity assessment, of which two have already passed.
effervescent tablets,vitamin c effervescent tablets,Dietary Supplement ,Nutritional Supplements
FOSHAN PHARMA CO., LTD. , https://www.foshanmedicine.com